Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome

ABSTRACT: Previous studies showed that the anti-rheumatic agent auranofin inhibits the NLRP3 inflammasome; thus, this study evaluate the anti-fibrotic effect of auranofin in vivo and explored the underlying molecular mechanism. The antifibrotic effect of auranofin is assessed in thioacetamide- and carbon tetrachloride-induced liver fibrosis models. In this study, we use RNA-sequencing in hepatic stellate cell (HSC), and bone marrow-derived macrophage (BMDM) to examine the underlying mechanism of auranofin.

ORGANISM(S): Mus musculus

PROVIDER: GSE176346 | GEO | 2021/06/08

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome

Project description:Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome

| PRJNA735867 | ENA

Entamoeba histolytica and auranofin treatment

Project description:2 million E. histolytica HM1:IMSS was treated with 0.5% DMSO for 3 h and 2 million E. histolytica HM1:IMSS was treated with 1 M-5M auranofin for 3 h

2012-02-03 | E-MEXP-3494 | biostudies-arrayexpress

Auranofin Fosters Regulatory T Cell Expansion and Augmented Tumor Burden in Mice

Project description:Auranofin, an FDA-approved antirheumatic drug, has been reported to have anti-tumoral properties but its immunological effects and significance are not well understood. This study is the first to report auranofin-induced regulatory T cell (Treg) expansion. In a mouse model with B16F10 melanoma, auranofin treatment surprisingly resulted in increased lung tumor coverage, elevated serum IL-10 levels, and a higher frequency of FOXP3+ CD44+ CD4 T cells in the spleen compared to vehicle controls. We also noted significant differences in the relative proportions of antigen presenting cells (APCs), namely, B cells and dendritic cells (DCs). To determine if auranofin promotes Treg expansion independently of tumor-specific antigens or tumor burden, we stimulated T cell receptors ex vivo in lymph node cultures from naïve mice using anti-CD3ε/CD28 in the presence or absence of auranofin. Auranofin-treated cultures showed significantly higher Treg frequencies than controls. This phenomenon was also observed in peripheral blood mononuclear cell (PBMC) cultures from healthy donors. Results from auranofin and a specific thioredoxin reductase 1 (TRXR1) inhibitor, TRi-1, suggest that NRF2 activation through TRXR1 blockade may promote Treg expansion and immune suppression in both mice and humans. By using NCF1 deficient mice conditionally expressing functional NCF1, we found that B cell or DC specific ROS was sufficient in augmenting B16F10 tumor burden and were comparable to TRXR1 inhibitor treatment in NCF1 mutant and wild type mice. These results suggest elevated TRXR1 inhibitor induced ROS levels in APCs could trigger Treg expansion. Finally, these findings provide a rationale for the divergent anti-tumoral responses observed in auranofin-treated immunocompetent versus immunocompromised cancer models. Given the ongoing clinical trials exploring auranofin as an anti-cancer agent, this study could have clinical significance.

2025-12-08 | PXD069997 | Pride

Auranofin Fosters Regulatory T Cell Expansion and Augmented Tumor Burden in Mice

2025-12-08 | PXD060423 | Pride

Accumulation of auranofin in white adipose tissues lowers leptin levels and exerts anti-diabetic effects

Project description:Low-grade, sustained inflammation in white adipose tissue (WAT) characterizes obesity and frequently coincides with insulin resistance and type 2 diabetes (T2D). However, pharmacological targeting of WAT inflammation lacks durable therapeutic effects. Through a computational screen, we identified the FDA-approved rheumatoid arthritis drug auranofin is a putative small molecule for obesity treatment. We discovered that allometrically scaled safe auranofin doses homed to WAT and improved insulin sensitivity in obese wild-type mice. To assess the transcriptional changes underlying the beneficial effects of auranofin, we performed RNA-seq analysis on adipose and liver tissue after 4 weeks of treatment with vehicle or auranofin.

2022-10-06 | GSE202935 | GEO

Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome.

Project description: Not available

| S-EPMC8245406 | biostudies-literature

Characterization of Entamoeba histolytica adapted to auranofin by combined transcriptomics and redox proteomics

Project description:Purpose: Transcriptome characterization of Entamoeba histolytica trophozoites adapted to Auranofin Total RNA was extracted from control trophozoites (WT) and AFAT using the TRI reagent kit, according to the manufacturer instructions (Sigma-Aldrich USA). 6 RNAseq libraries were produced according to manufacturer protocol (NEBNext UltraII Directional RNA Library Prep Kit for Illumina, cat no. E7760) using 800ng total RNA. mRNAs pull-up was performed using Magnetic Isolation Module (NEB, cat no. E7490). All libraries were mixed into a single tube with equal molarity. The RNAseq data was generated on Illumina NextSeq500, 75 single-end read, high output mode (Illumina, cat no. 200249) The number of reads per gene was counted using Htseq-count (v0.9.1) Results: Transcriptomics of Entamoeba histolytica trophozoites that were adapted to 2 uM Auranofin revealed an upregulation of genes encoding cytoskeletal proteins, dehydrogenases and guanyl-nucleotide exchange factors. Conclusions: Adaptation to Auranofin comes with a fitness cost for E.histolytica that includes a decreased growth rate and virulence and sensitivity to Oxidative stress, Nitrosative stress and to Metronidazole. Overexpression of genes whose products are sensitive to Auranofin-mediated oxidation may represent an important step in the adaptation process to Auranofin and EhTrxR does not seem to be central for this process.

2021-08-31 | GSE178520 | GEO

Transcriptome analysis of Candida albicans treated with auranofin

Project description:Candida albicans lab strain SC5314 was grown in YPD broth at 30C°C from OD=66=0.1 till 1.0. The culture was divided into two batches. One batch was treated with 16 μg/mL auranofin. The other batch was treated with the same volume of vehicle (DMSO). After three hours, cells were harvested for RNA-Seq.

2026-04-30 | E-MTAB-16895 | biostudies-arrayexpress

Repurposing Auranofin, an Anti-Rheumatic Gold Compound, to Treat Acne Vulgaris by Targeting the NLRP3 Inflammasome.

Project description: Not available

| S-EPMC7457177 | biostudies-literature

Gene Regulatory Network-Driven Drug Repurposing Identifies Anti-Atherosclerotic Properties of Auranofin.

Project description:Gene Regulatory Network-Driven Drug Repurposing Identifies Anti-Atherosclerotic Properties of Auranofin.

| PRJNA1246056 | ENA